SMAD2 and colorectal cancer: Moreover, specific siRNA targeting NRP2 or treatment with pharmacological inhibitors of TGFβ-1 type 1 receptor (TGFβRI) prevented Smad2/3 phosphorylation and the NRP2-mediated EMT of colorectal cancer cells.